Results from a Phase II trial for cardiovascular disease with an epigenetic target therapy show promise.
Daily News Roundup
Results from a Phase II trial for cardiovascular disease with an epigenetic target therapy show promise.
A human trial of a hepatitis C treatment is shut down after one of the participants died.
Another person has died from the rodent-borne disease after visiting Yosemite National Park.
Researchers consider the recent reappearance of West Nile virus in Texas and the efforts to control it.
A polar bear in a German zoo dies after contracting a virus normally found in zebras.
Myriad Genetics can hold patents on the BRAC1 and BRAC2 oncogenes, but not on tests comparing DNA sequences.
A former manager at Genentech claims the company bypassed ethical and clinical guidelines in order to rush a promising drug through clinical trials.
Patent expirations of one HIV drugs will make the disease cheaper—but also more cumbersome—to treat.
A researcher from the John Wayne Cancer Institute has settled his scientific misconduct case with the Office of Research Integrity.
Australian trout are susceptible to skin cancer, according to a new study—the first evidence that wild fish can be afflicted by the disease.